A new trading day began on Friday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price up 7.71% from the previous day of trading, before settling in for the closing price of $0.62. CTMX’s price has ranged from $0.60 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 36.21% over the last five years. Meanwhile, its annual earnings per share averaged -108.95%. With a float of $78.05 million, this company’s outstanding shares have now reached $80.10 million.
The firm has a total of 121 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.33%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 2.56%, while institutional ownership is 58.41%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -108.95% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.06 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Analysing the last 5-days average volume posted by the [CytomX Therapeutics Inc, CTMX], we can find that recorded value of 10.63 million was better than the volume posted last year of 1.97 million. As of the previous 9 days, the stock’s Stochastic %D was 17.44%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 7.91%, which indicates a significant decrease from 28.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.38% in the past 14 days, which was lower than the 70.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8563, while its 200-day Moving Average is $1.1505. Now, the first resistance to watch is $0.7484. This is followed by the second major resistance level at $0.8320. The third major resistance level sits at $0.8869. If the price goes on to break the first support level at $0.6099, it is likely to go to the next support level at $0.5550. Now, if the price goes above the second support level, the third support stands at $0.4714.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 53.26 million, the company has a total of 78,259K Shares Outstanding. Currently, annual sales are 101,210 K while annual income is -570 K. The company’s previous quarter sales were 33,430 K while its latest quarter income was 5,740 K.
